SEARCH

SEARCH BY CITATION

References

  • 1
    Brodey RS, Goldschmidt MH and Roszel JR. Canine mammary neoplasms. Journal of the American Animal Hospital Association 1983; 19: 6190.
  • 2
    Sorenmo K. Canine mammary gland tumors. Veterinary Clinics of North America: Small Animal Practice 2003; 33: 573596.
  • 3
    Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781792.
  • 4
    Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147155.
  • 5
    Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J and Goldschmidt MH. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Veterinary and Comparative Oncology 2009; 7: 162172.
  • 6
    Klopfleisch R, Lenze D, Hummel M and Gruber AD. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 2010; 10: 618.
  • 7
    Rivera P and von Euler H. Molecular biological aspects on canine and human mammary tumors. Veterinary Pathology 2011; 48: 132146.
  • 8
    Welsch CW and Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Research 1977; 37: 951963.
  • 9
    Yokoro K, Nakano M, Ito A, Nagao K and Kodama Y. Role of prolactin in rat mammary carcinogenesis: detection of carcinogenicity of low-dose carcinogens and of persisting dormant cancer cells. Journal of the National Cancer Institute 1977; 58: 17771783.
  • 10
    Pearson OH, Manni A, Chambers M, Brodkey J and Marshall JS. Role of pituitary hormones in the growth of human breast cancer. Cancer Research 1978; 38: 43234326.
  • 11
    Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL, Millis RR and Cuzick J. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. International Journal of Cancer 1981; 28: 673676.
  • 12
    Clevenger CV, Furth PA, Hankinson SE and Schuler LA. The role of prolactin in mammary carcinoma. Endocrine Reviews 2003; 24: 127.
  • 13
    Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. Journal of Applied Toxicology 2005; 25: 179183.
  • 14
    Ginsburg E and Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995; 55: 25912595.
  • 15
    Goffin V, Touraine P, Pichard C, Bernichtein S and Kelly PA. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Molecular and Cellular Endocrinology 1999; 151: 7987.
  • 16
    Goffin V, Binard N, Touraine P and Kelly PA. Prolactin: the new biology of an old hormone. Annual Review of Physiology 2002; 64: 4767.
  • 17
    Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Disease 2005–2006; 24: 315.
  • 18
    Harvey PW, Everett DJ and Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Human & Experimental Toxicology 2006; 25: 395404.
  • 19
    Hamilton JM, Knight PJ, Beevers J and Else RW. Serum prolactin concentrations in canine mammary cancer. Veterinary Record 1978; 102: 127128.
  • 20
    El Etreby MF, Muller-Peddinghaus R, Bhargava AS, El Bab MR, Graf KJ and Trautwein G. The role of the pituitary gland in spontaneous canine mammary tumorigenesis. Veterinary Pathology 1980; 17: 216.
  • 21
    Rutteman GR, Willekes-Koolschijn N, Bevers MM, Van der Gugten AA and Misdorp W. Prolactin binding in benign and malignant mammary tissue of female dogs. Anticancer Research 1986; 6: 829835.
  • 22
    Rutteman GR, Bevers MM, Misdorp W and Van den Brom WE. Anterior pituitary function in female dogs with mammary tumors: II. Prolactin. Anticancer Research 1989; 9: 241245.
  • 23
    Cooke NE and Liebhaber SA. Molecular biology of the growth hormone-prolactin gene system. Vitamins and Hormones 1995; 50: 385459.
  • 24
    Freeman ME, Kanyicska B, Lerant A and Nagy G. Prolactin: structure, function, and regulation of secretion. Physiological Reviews 2000; 80: 15231631.
  • 25
    Ben-Jonathan N, Mershon JL, Allen DL and Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews 1996; 17: 639669.
  • 26
    Katznelson L, Riskind PN, Saxe VC and Klibanski A. Prolactin pulsatile characteristics in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism 1998; 83: 761764.
  • 27
    De Coster R, Beckers JF, Beerens D and De Mey J. A homologous radioimmunoassay for canine prolactin: plasma levels during the reproductive cycle. Acta Endocrinologica 1983; 103: 473478.
  • 28
    Silberstein GB. Postnatal mammary gland morphogenesis. Microscopy Research and Technique 2001; 52: 155162.
  • 29
    Brisken CB and O'Malley B. Hormone action in the mammary gland. Cold Spring Harbor Perspectives in Biology 2010; 2: a003178.
  • 30
    McKiernan JF and Hull D. Breast development in the newborn. Archives of Disease in Childhood 1981; 56: 525529.
  • 31
    Anderson LL, Dyck GW, Mori H, Henricks DM and Melampy RM. Ovarian function in pigs following hypophysial stalk transection or hypophysectomy. American Journal of Physiology 1967; 212: 11881194.
  • 32
    Kooistra HS and Okkens AC. Secretion of growth hormone and prolactin during progression of the luteal phase in healthy dogs: a review. Molecular and Cellular Endocrinology 2002; 197: 167172.
  • 33
    Joechle W. Prolactin in canine and feline reproduction. Reproduction in Domestic Animals 1997; 32: 183193.
  • 34
    Fernandez I, Touraine P and Goffin V. Prolactin and human tumourogenesis. Journal of Neuroendocrinology 2010; 22: 771777.
  • 35
    Galsgaard ED, Rasmussen BB, Folkesson CG, Rasmussen LM, Berchtold MW, Christensen L and Panina S. Re-evaluation of the prolactin receptor expression in human breast cancer. Journal of Endocrinology 2009; 201: 115128.
  • 36
    Ben-Jonathan N, LaPensee CR and LaPensee EW. What can we learn from rodents about prolactin in humans? Endocrine Reviews 2008; 29: 141.
  • 37
    Trott JF, Schennink A and Hovey RC. Cloning and expression of a unique short form of the porcine prolactin receptor. Journal of Molecular Endocrinology 2011; 46: 5162.
  • 38
    Kline JB and Clevenger CV. Identification and characterization of the prolactin-binding protein in human serum and milk. Journal of Biological Chemistry 2001; 276: 2476024766.
  • 39
    Welsch CW, Louks G, Fox D and Brooks C. Enhancement by prolactin of carcinogen induced mammary cancerigenesis in the male rat. British Journal of Cancer 1975; 32: 427431.
  • 40
    Fields K, Kulig E and Lloyd RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Laboratory Investigation 1993; 68: 354360.
  • 41
    Kurtz A, Bristol LA, Tóth BE, Lazar-Wesley E, Takács L and Kacsóh B. Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. Biology of Reproduction 1993; 48: 10951103.
  • 42
    Zinger M, McFarland M and Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. Journal of Clinical Endocrinology and Metabolism 2003; 88: 689696.
  • 43
    Vonderhaar BK. Prolactin: the forgotten hormone of human breast cancer. Pharmacology & Therapeutics 1998; 79: 169178.
  • 44
    Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E and Lokshin AE. Biological significance of prolactin in gynecologic cancers. Cancer Research 2009; 69: 52265233.
  • 45
    Jacobson EM, Hugo ER, Borcherding DC and Ben-Jonathan N. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discovery Medicine 2011; 11: 315324.
  • 46
    Selman PJ, Mol JA, Rutteman GR, van Garderen E and Rijnberk A. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 1994; 134: 287292.
  • 47
    van Garderen E, Swennenhuis JF, Hellmen E and Schalken JA. Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. Domestic Animal Endocrinology 2001; 20: 123135.
  • 48
    Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B and Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 1999; 91: 629634.
  • 49
    Tworoger SS, Sluss P and Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Research 2006; 66: 24762482.
  • 50
    Tworoger SS, Eliassen AH, Sluss P and Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. Journal of Clinical Oncology 2007; 25: 14821488.
  • 51
    Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR and Trivedi TI. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. European Journal of Surgical Oncology 2000; 26: 540547.
  • 52
    Mujagic Z and Mujagic H. Importance of serum prolactin determination in metastatic breast cancer patients. Croatian Medical Journal 2004; 45: 176180.
  • 53
    Mujagic Z, Mujagic H and Prnjavorac B. Circulating levels of prolactin in breast cancer patients. Medical Archives 2005; 59: 3335.
  • 54
    Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R and Avorn J. Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry 2002; 59: 11471154.
  • 55
    Eliassen AH, Tworoger SS and Hankinson SE. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. International Journal of Cancer 2007; 120: 15361541.
  • 56
    Tworoger SS and Hankinson SE. Prolactin and breast cancer risk. Cancer Letters 2006; 243: 160169.
  • 57
    Di Carlo R, Muccioli G, Bellussi G, Lando D and Mussa A. Presence and characterization of prolactin receptors in human benign breast tumours. European Journal of Cancer & Clinical Oncology 1984; 20: 635638.
  • 58
    Holdaway IM and Friesen HG. Hormone binding by human mammary carcinoma. Cancer Research 1977; 37: 19461952.
  • 59
    Di Carlo R and Muccioli G. Prolactin receptor in human mammary carcinoma. Tumori 1979; 65: 695702.
  • 60
    Thorpe SM and Daehnfeldt JL. Specific binding of prolactin in human mammary tumours. In: Breast Cancer: Experimental and Clinical Aspects. HT Mouridson and T Palshof eds., Oxford, Pergamon Press, 1980: 4551.
  • 61
    Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, Nicholson RI and Sutherland RL. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. Journal of Clinical Endocrinology & Metabolism 1997; 82: 36923699.
  • 62
    Reynolds C, Montone KT, Powell CM, Tomaszewski JE and Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997; 138: 55555560.
  • 63
    Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F and Kelly PA. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. Journal of Clinical Endocrinology & Metabolism 1998; 83: 667674.
  • 64
    Ferreira M, Mesquita M, Quaresma M and Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 2008; 53: 5661.
  • 65
    Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT and Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. The American Journal of Pathology 1995; 146: 695705.
  • 66
    Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE and Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. International Journal of Cancer 1998; 79: 202211.
  • 67
    Peirce SK, Chen WY and Chen WY. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. Journal of Endocrinology 2001; 171: R1R4.
  • 68
    Gill S, Peston D, Vonderhaar BK and Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. Journal of Clinical Pathology 2001; 54: 956960.
  • 69
    Meng J, Tsai-Morris CH and Dufau ML. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Research 2004; 64: 56775682.
  • 70
    McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA and Clevenger CV. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology 2008; 21: 565571.
  • 71
    Plotnikov A, Varghese B, Tran TH, Liu C, Rui H and Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Research 2009; 69: 31653172.
  • 72
    Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. Journal of Cellular Physiology 2003; 197: 157168.
  • 73
    Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK and Rui H. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Research 2010; 70: 17111721.
  • 74
    Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE, Spiegelman VS and Fuchs SY. Stabilization of prolactin receptor in breast cancer cells. Oncogene 2006; 25: 18961902.
  • 75
    Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V and Touraine P. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proceedings of the National Academy of Sciences 2008; 105: 1453314538.
  • 76
    Courtillot C, Chakhtoura Z, Bogorad R, Genestie C, Bernichtein S, Badachi Y, Janaud G, Akakpo JP, Bachelot A, Kuttenn F, Goffin V and Touraine P. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas. Journal of Clinical Endocrinology & Metabolism 2010; 95: 271279.
  • 77
    Carver KC, Arendt LM and Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Molecular and Cellular Endocrinology 2009; 307: 17.
  • 78
    Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ and Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Research 2006; 66: 18241832.
  • 79
    Wagner KU and Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia 2008; 13: 93103.
  • 80
    Dong J, Tsai-Morris CH and Dufau ML. A novel estradiol/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor. The Journal of Biological Chemistry 2006; 281: 1882518836.
  • 81
    Duan R, Ginsburg E and Vonderhaar BK. Estrogen stimulates transcription from the human prolactin distal promotor through AP1 and estrogen responsive elements in T47D human breast cancer cells. Molecular and Cellular Endocrinology 2008; 281: 918.
  • 82
    Rasmussen LM, Frederiksen KS, Din N, Galsgaard E, Christensen L, Berchtold MW and Panina S. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocrine-Related Cancer 2010; 17: 809822.
  • 83
    Tworoger SS, Eliassen AH, Rosner B, Sluss P and Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Research 2004; 64: 68146819.
  • 84
    Gonzalez L, Zambrano A, Lazaro-Trueba I, Lopez E, Gonzalez JJ, Martin-Perez J and Aranda A. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 2009; 28: 12981308.
  • 85
    Vonderhaar BK. Prolactin involvement in breast cancer. Endocrine-Related Cancer 1999; 6: 389404.
  • 86
    Goffin V, Bernichtein S, Touraine P and Kelly PA. Development and potential clinical use of human prolactin receptor antagonists. Endocrine Reviews 2005; 26: 400422.
  • 87
    Jacobson EM, Hugo ER, Tuttle TR, Papoian R and Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends in Endocrinology & Metabolism 2010; 21: 691698.
  • 88
    Kreeger TJ and Seal US. Circannual prolactin rhythm in intact dogs housed outdoors. Chronobiologia 1992; 19: 18.
  • 89
    Gobello C, Bolognani F, de la Sota RL and Goya RG. Twenty-four-hour profiles of serum prolactin and luteinizing hormone in anoestrous crossbred bitches. Reproduction in Domestic Animals 2001; 36: 4145.
  • 90
    Corrada Y, Castex G, Sosa Y and Gobello C. Secretory patterns of prolactin in dogs: circannual and ultradian rhythms. Reproduction in Domestic Animals 2003; 38: 219223.
  • 91
    Corrada Y, Rimoldi I, Arreseigor S, Marecco G and Gobello C. Prolactin reference range and pulsatility in male dogs. Theriogenology 2006; 66: 15991602.
  • 92
    Sinha YN, Salocks CB and Vanderlaan WP. Prolactin and growth hormone levels in different inbred strains of mice: patterns in association with estrous cycle, time of day, and perphenazine stimulation. Endocrinology 1975; 97: 11121122.
  • 93
    Urhausen C, Seefeldt A, Eschricht FM, Koch A, Hoppen HO, Beyerbach M, Mohrke C, Dieleman SJ and Gunzel-Apel AR. Concentrations of prolactin, LH, testosterone, TSH and thyroxine in normospermic dogs of different breeds. Reproduction in Domestic Animals 2009; 44: 279282.
  • 94
    Kooistra HS and Okkens AC. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reproduction in Domestic Animals 2001; 36: 115119.
  • 95
    Gobello C, Colombani M, Scaglia H, De La Sota RL and Goya RG. Heterogeneity of circulating prolactin in the bitch. Reproduction Nutrition Development 2001; 41: 505511.
  • 96
    Hashimoto O, Yonezawa T, Sugiyama Y, Kawaminami M and Hasegawa Y. Molecular cloning and expression of canine prolactin gene. Experimental Animals 2010; 59: 643646.
  • 97
    Dorn CR, Taylor DO, Schneider R, Hibbard HH and Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 1968; 40: 307318.
  • 98
    Schneider R, Dorn CR and Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. Journal of the National Cancer Institute 1969; 43: 12491261.
  • 99
    Taylor GN, Shabestari L, Williams J, Mays CW, Angus W and McFarland S. Mammary neoplasia in a closed beagle colony. Cancer Research 1976; 36: 27402743.
  • 100
    Misdorp W. Progestagens and mammary tumours in dogs and cats. Acta Endocrinologica 1991; 125: 2731.
  • 101
    Yamagami T, Kobayashi T, Takahashi K and Sugiyama M. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. Journal of Small Animal Practice 1996; 37: 462464.
  • 102
    Morris JS, Dobson JM, Bostock DE and O'Farrell E. Effect of ovariohysterectomy in bitches with mammary neoplasms. Veterinary Record 1998; 142: 656658.
  • 103
    Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW and Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. Journal of Veterinary Internal Medicine 2003; 17: 102106.
  • 104
    Sorenmo KU, Shofer FS and Goldschmidt MH. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. Journal of Veterinary Internal Medicine 2000; 14: 266270.
  • 105
    Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. European Journal of Cancer Prevention 1997; 6: 310.
  • 106
    Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, Ganguly S and Garte SJ. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detection and Prevention Journal 1999; 23: 232237.
  • 107
    Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 2000; 21: 4054.
  • 108
    Sorenmo KU, Rasotto R, Zappulli V and Goldschmidt MH. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Veterinary Pathology 2011; 48: 8597.
  • 109
    Stovring M, Moe L and Glattre E. A population-based case–control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. APMIS 1997; 105: 590596.
  • 110
    Rutteman GR. Contraceptive steroids and the mammary gland: Is there a hazard? Breast Cancer Research and Treatment 1992; 23: 2941.
  • 111
    Donnay I, Rauis J, Devleeschouwer N, Wouters-Ballman P, Leclercq G and Verstegen J. Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. American Journal of Veterinary Research 1995; 56: 11881194.
  • 112
    Rutteman GR, Misdorp W, Blankenstein MA and Van den Brom WE. Oestrogen and progestin receptors in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. British Journal of Cancer 1988; 58: 594599.
  • 113
    Perez Alenza MD, Pena L, del Castillo N and Nieto AI. Factors influencing the incidence and prognosis of canine mammary tumours. Journal of Small Animal Practice 2000; 41: 287291.
  • 114
    Moe L. Population-based incidence of mammary tumours in some dog breeds. Journal of reproduction and fertility. Supplement 2001; 57: 439443.
  • 115
    Zatloukal J, Lorenzova J, Tichy F, Necas A, Kecova H and Kohout P. Breed and age as risk factors for canine mammary tumours. Acta Veterinaria Brno 2005; 74: 103109.
  • 116
    Schafer KA, Kelly G, Schrader R, Griffith WC, Muggenburg A, Tierney LA, Lechner JF, Janovitz EB and Hahn FF. A canine model of familial mammary gland neoplasia. Veterinary Pathology 1998; 35: 168177.
  • 117
    Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gärtner F and Gruber AD. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Veterinary Pathology 2011; 48: 98116.
  • 118
    Humphreys RC and Hennighausen L. Transforming growth factor alpha and mouse models of human breast cancer. Oncogene 2000; 19: 10851091.
  • 119
    Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M and Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 2005; 18: 10271033.
  • 120
    DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd and Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. Journal of Clinical Oncology 2005; 23: 11521160.
  • 121
    Gama A, Gärtner F, Alves A and Schmitt F. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009; 87: 432437.
  • 122
    Kennedy KC, Qurollo BA, Rose BJ and Thamm DH. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. Veterinary and Comparative Oncology 2011; 9: 196206.
  • 123
    Rutteman GR, Foekens JA, Portengen H, Vos JH, Blankenstein MA, Teske E, Cornelisse CJ and Misdorp W. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Research and Treatment 1994; 30: 139146.
  • 124
    Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes C and Illera JC. Role of steroid hormones and prolactin in canine mammary cancer. The Journal of Steroid Biochemistry and Molecular Biology 2005; 94: 181187.
  • 125
    Michel E, Feldmann SK, Kowalewski MP, Rohrer Bley C, Boos A, Guscetti F and Reichler IM. Expression of prolactin receptor in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas. BMC Veterinary Research 2012; 8: 72.
  • 126
    Reichler IM, Pfeiffer E, Piche CA, Jöchle W, Roos M, Hubler M and Arnold S. Changes in plasma gonadotropin concentrations and urethral closure pressure in the bitch during the 12 months following ovariectomy. Theriogenology 2004; 62: 13911402.
  • 127
    Martin LJM, Siliart B, Dumon HJW and Nguyen P. Spontaneous hormonal variations in male cats following gonadectomy. Journal of Feline Medicine and Surgery 2006; 8: 309314.
  • 128
    Guenzel-Apel AR, Seefeldt A, Eschricht FM, Urhausen C, Kramer S, Mischke R, Hoppen HO, Beyerbach M, Koivisto M and Dieleman SJ. Effects of gonadectomy on prolactin and LH secretion and the pituitary-thyroid axis in male dogs. Theriogenology 2009; 71: 746753.